HighVista Strategies’s Ascendis Pharma A/S ASND Stock Holding History

HighVista Strategies’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,781	Closed	-$1.32M	–	150
2026 Q1	$1.32M	Buy	5,781 +2,121	+58%	+$475K	0.37%	89
2025 Q4	$780K	Sell	3,660 -3,422	-48%	-$707K	0.2%	123
2025 Q3	$1.41M	Buy	7,082 +4,108	+138%	+$766K	0.35%	91
2025 Q2	$513K	Sell	2,974 -3,098	-51%	-$505K	0.19%	126
2025 Q1	$946K	Hold	6,072	–	–	0.36%	115
2024 Q4	$836K	Buy	+6,072	New	+$798K	0.31%	108
2024 Q3	–	Sell	-4,527	Closed	-$617K	–	144
2024 Q2	$617K	Hold	4,527	–	–	0.23%	113
2024 Q1	$684K	Buy	4,527 +1,699	+60%	+$242K	0.24%	107
2023 Q4	$356K	Sell	2,828 -3,070	-52%	-$306K	0.13%	122
2023 Q3	$552K	Buy	5,898 +1,723	+41%	+$161K	0.26%	94
2023 Q2	$373K	Sell	4,175 -3,163	-43%	-$275K	0.17%	129
2023 Q1	$787K	Hold	7,338	–	–	0.64%	50
2022 Q4	$896K	Sell	7,338 -2,442	-25%	-$284K	0.53%	52
2022 Q3	$1.01M	Buy	9,780 +2,338	+31%	+$222K	0.58%	43
2022 Q2	$692K	Sell	7,442 -379	-5%	-$35.7K	0.42%	56
2022 Q1	$918K	Sell	7,821 -720	-8%	-$83.4K	0.58%	41
2021 Q4	$1.15M	Sell	8,541 -1,228	-13%	-$183K	0.91%	36
2021 Q3	$1.56M	Buy	9,769 +3,709	+61%	+$508K	1.03%	17
2021 Q2	$797K	Buy	6,060 +555	+10%	+$74K	0.57%	49
2021 Q1	$709K	Buy	5,505 +774	+16%	+$118K	0.53%	38
2020 Q4	$789K	Buy	4,731 +1,424	+43%	+$235K	0.5%	47
2020 Q3	$510K	Buy	3,307 +414	+14%	+$59.5K	0.37%	48
2020 Q2	$428K	Buy	+2,893	New	+$397K	0.35%	42

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

HighVista Strategies's ASND Position: Q2 2026 in Review

HighVista Strategies sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 5,781 shares — an estimated $1.32M sold.

HighVista Strategies first reported a position in ASND in Q2 2020 and held it in 23 quarters. The position peaked at $1.56M in Q3 2021. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

HighVista Strategies reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
HighVista Strategies sold 5,781 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.32M.
HighVista Strategies first reported a position in Ascendis Pharma A/S in Q2 2020 and held it in 23 quarters.
HighVista Strategies's Ascendis Pharma A/S position peaked at $1.56M in Q3 2021.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.